FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061024307> ?p ?o ?g. }

• W2061024307 endingPage "6" @default.
• W2061024307 startingPage "1" @default.
• W2061024307 abstract "Epithelial ovarian cancer remains the leading cause of death from gynecologic cancer in the United States with an estimated 15,300 deaths in 2006 [ [1] Jemal A. Siegel R. Ward E. Murray T. Xu J. Smigal C. et al. Cancer Statistics, 2006. CA Cancer J. Clin. 2006; 56: 106-130 Crossref PubMed Scopus (5485) Google Scholar ]. Cytoreductive surgery, the cornerstone of initial therapy, is followed by chemotherapy for management of residual disease. Two randomized trials [ 2 McGuire W.P. Hoskins W.J. Brady M.F. Kucera P.R. Partridge E.E. Look K.Y. et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 1996; 334: 1-6 Crossref PubMed Scopus (2740) Google Scholar , 3 Piccart M.J. Bertelsen K. James K. Cassidy J. Mangioni C. Simonsen E. et al. Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J. Natl. Cancer Inst. 2000; 92: 699-708 Crossref PubMed Scopus (898) Google Scholar ] established cisplatin plus paclitaxel (24-h infusion) to be the standard of care in the 1990s, and subsequent larger randomized trials [ 4 Ozols R.F. Bundy B.N. Greer B.E. Fowler J.M. Clarke-Pearson D. Burger R.A. et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 2003; 21: 3194-3200 Crossref PubMed Scopus (1741) Google Scholar , 5 du Bois A. Lück H.-J. Meier W. Adams H.P. Mobus V. Costa S. et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 2003; 95: 1320-1330 Crossref PubMed Google Scholar ] demonstrated that carboplatin with paclitaxel (3-h infusion) was the preferable regimen due to a reduction in toxicity, superior quality of life, increased ease of administration, and no evidence of inferiority compared to cisplatin/paclitaxel. A recent international consensus conference recommended intravenous (IV) carboplatin/paclitaxel as the standard regimen against which new treatments should be compared [ [6] du Bois A. Quinn M. Thigpen T. Vermorken J. Avall-Lundquist E. Bookman M. et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann. Oncol. 2005; 16: viii7-viii12 Crossref PubMed Scopus (402) Google Scholar ]. The intraperitoneal (IP) delivery of chemotherapy, particularly cisplatin, has been posited to improve long-term outcomes for women with advanced ovarian cancer based on results from phase III trials. However, interpretation of these data has generated controversy, primarily due to the increased toxicity associated with IP therapy and to the control arms used in the randomized trials. In the recent phase III trials of IP therapy, the control arm consisted of the outdated regimen of IV cisplatin and 24-h paclitaxel. Based on an exploratory cross-trial analysis, we hypothesize that there is no statistically significant improvement in survival if the IP regimen were compared to the current global standard of IV carboplatin and 3-h paclitaxel. Potential reasons to explain this outcome are addressed, as well as justification for a new randomized trial to prospectively evaluate the hypothesis." @default.
• W2061024307 created "2016-06-24" @default.
• W2061024307 creator A5037650974 @default.
• W2061024307 creator A5047695952 @default.
• W2061024307 creator A5058244284 @default.
• W2061024307 creator A5075213038 @default.
• W2061024307 creator A5086638104 @default.
• W2061024307 creator A5086907081 @default.
• W2061024307 date "2006-10-01" @default.
• W2061024307 modified "2023-10-16" @default.
• W2061024307 title "Intraperitoneal cisplatin therapy in ovarian cancer: Comparison with standard intravenous carboplatin and paclitaxel" @default.
• W2061024307 cites W1758230404 @default.
• W2061024307 cites W1863225814 @default.
• W2061024307 cites W1922469696 @default.
• W2061024307 cites W1940922428 @default.
• W2061024307 cites W1942713680 @default.
• W2061024307 cites W1963592300 @default.
• W2061024307 cites W2016888963 @default.
• W2061024307 cites W2097105130 @default.
• W2061024307 cites W2109350154 @default.
• W2061024307 cites W2130941707 @default.
• W2061024307 cites W2135109254 @default.
• W2061024307 cites W2135586336 @default.
• W2061024307 cites W2143219457 @default.
• W2061024307 cites W2154175915 @default.
• W2061024307 cites W2156804105 @default.
• W2061024307 cites W2222529560 @default.
• W2061024307 cites W2222925056 @default.
• W2061024307 cites W2290371619 @default.
• W2061024307 cites W2316501478 @default.
• W2061024307 cites W2328421677 @default.
• W2061024307 doi "https://doi.org/10.1016/j.ygyno.2006.06.026" @default.
• W2061024307 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16904166" @default.
• W2061024307 hasPublicationYear "2006" @default.
• W2061024307 type Work @default.
• W2061024307 sameAs 2061024307 @default.
• W2061024307 citedByCount "56" @default.
• W2061024307 countsByYear W20610243072012 @default.
• W2061024307 countsByYear W20610243072013 @default.
• W2061024307 countsByYear W20610243072014 @default.
• W2061024307 countsByYear W20610243072015 @default.
• W2061024307 countsByYear W20610243072017 @default.
• W2061024307 countsByYear W20610243072018 @default.
• W2061024307 countsByYear W20610243072019 @default.
• W2061024307 countsByYear W20610243072020 @default.
• W2061024307 crossrefType "journal-article" @default.
• W2061024307 hasAuthorship W2061024307A5037650974 @default.
• W2061024307 hasAuthorship W2061024307A5047695952 @default.
• W2061024307 hasAuthorship W2061024307A5058244284 @default.
• W2061024307 hasAuthorship W2061024307A5075213038 @default.
• W2061024307 hasAuthorship W2061024307A5086638104 @default.
• W2061024307 hasAuthorship W2061024307A5086907081 @default.
• W2061024307 hasConcept C121608353 @default.
• W2061024307 hasConcept C126322002 @default.
• W2061024307 hasConcept C143998085 @default.
• W2061024307 hasConcept C2776694085 @default.
• W2061024307 hasConcept C2777292972 @default.
• W2061024307 hasConcept C2778239845 @default.
• W2061024307 hasConcept C2780427987 @default.
• W2061024307 hasConcept C2780435969 @default.
• W2061024307 hasConcept C2781451048 @default.
• W2061024307 hasConcept C29456083 @default.
• W2061024307 hasConcept C71924100 @default.
• W2061024307 hasConceptScore W2061024307C121608353 @default.
• W2061024307 hasConceptScore W2061024307C126322002 @default.
• W2061024307 hasConceptScore W2061024307C143998085 @default.
• W2061024307 hasConceptScore W2061024307C2776694085 @default.
• W2061024307 hasConceptScore W2061024307C2777292972 @default.
• W2061024307 hasConceptScore W2061024307C2778239845 @default.
• W2061024307 hasConceptScore W2061024307C2780427987 @default.
• W2061024307 hasConceptScore W2061024307C2780435969 @default.
• W2061024307 hasConceptScore W2061024307C2781451048 @default.
• W2061024307 hasConceptScore W2061024307C29456083 @default.
• W2061024307 hasConceptScore W2061024307C71924100 @default.
• W2061024307 hasIssue "1" @default.
• W2061024307 hasLocation W20610243071 @default.
• W2061024307 hasLocation W20610243072 @default.
• W2061024307 hasOpenAccess W2061024307 @default.
• W2061024307 hasPrimaryLocation W20610243071 @default.
• W2061024307 hasRelatedWork W1502181122 @default.
• W2061024307 hasRelatedWork W2039658173 @default.
• W2061024307 hasRelatedWork W2154175915 @default.
• W2061024307 hasRelatedWork W2280856801 @default.
• W2061024307 hasRelatedWork W2311734504 @default.
• W2061024307 hasRelatedWork W2328421677 @default.
• W2061024307 hasRelatedWork W2380099415 @default.
• W2061024307 hasRelatedWork W2419075599 @default.
• W2061024307 hasRelatedWork W248568554 @default.
• W2061024307 hasRelatedWork W4250038123 @default.
• W2061024307 hasVolume "103" @default.
• W2061024307 isParatext "false" @default.
• W2061024307 isRetracted "false" @default.
• W2061024307 magId "2061024307" @default.
• W2061024307 workType "article" @default.